Background

Founded in 2018, Biotheus (BioNTech) develops innovative biologics for cancer and autoimmune diseases. With over 20 Class I biologics in pipeline, it has multiple candidates in clinical stages.

The company has R&D centers in Zhuhai, Suzhou, and Hong Kong, clinical teams in Shanghai and Beijing, and a production base in BioSpark Nantong. Its GMP-compliant (NMPA/FDA/EMA) facility features 2000L bioreactors and high-speed filling lines.

Case detail

• Total Investment: RMB 5 billion (phase I)

• Site Area: 61,000 m²

• Products: 10 million doses of antibodies and cell therapies per year

• Provides high-quality bio-lab products for the Chinese market